Ntra-2112
Intestinal Malabsorption
Elgan Pharma Ltd.Phase 3Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Intestinal Malabsorption cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Elgn-2112 Elgan Pharma Ltd. | Phase 3 | BB |
LIDOCAINE Hospital Infantil Cândido Fontoura | Phase 3 | BB |
TANNIC ACID Hospital Infantil Cândido Fontoura | Phase 3 | BB |
Nexvax2 ImmusanT, Inc. | Phase 2 | B |
Crofelemer Napo Therapeutics, S.p.A. | Phase 2 | CCC |
LACTOSE UREIDE University Hospital, Bonn | D | |
Calcium Hvidovre University Hospital | N/A | D |
METRONIDAZOLE HaEmek Medical Center, Israel | N/A | D |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →